Differential Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Platelet, Endothelial and Vascular Function

Healthy Clinical Trial

Official title:

Investigation Into Incorporation of (n-3) Polyunsaturated Fatty Acids Into Erythrocyte Membranes and Clearance, and Effects on Platelet Function, Arterial Function and Endothelial Repair

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01735357
• Other study ID #: EDT
• Status: Completed
• Phase: N/A
• Start date: June 2009
• Est. completion date: April 2010

Study information

• Verified date: September 2019
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to determine whether supplementation with oils enriched with long chain n-3 PUFA, either EPA or DHA, had a differential effect on platelet, endothelial and vascular function.

Description:

Relatively few studies have made a head-to-head comparison of DHA (22:6n-3) with EPA (20:5n-3). The understanding of this differential effect may be of great interest in populations with low EPA intake such as vegetarians, who may choose to supplement their dietary intake of long-chain n-3 PUFA in the form of DHA-rich algal oil.

This study aimed to investigate the effect of supplementation with oils rich in either EPA or DHA (3g/day, 6 weeks) in healthy young males on platelet, endothelial and vascular function, as well as other CVD risk factors. The primary outcomes were platelet monocyte aggregates and endothelial progenitor cells - novel markers of platelet and endothelial function, measured by flow cytometry, Secondary outcomes included capillary density, measured by capillaroscopy to assess changes in microvascular function, pulse wave analysis, digital volume pulse and ambulatory blood pressure. Other secondary outcomes included lipid profiles (TAG, cholesterol, NEFA), glycaemic control (HOMA, QUICKI) and oxidative stress (isoprostane). The omega-3 index (erythrocyte EPA+DHA) was used as a marker of compliance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy males

• No smokers

• Aged 18-45y old

• Able to understand the information sheet and comply with all the trial procedures

• Having given written consent to take part in the study prior to participation.

Exclusion Criteria:

• Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke, dyslipidemia), diabetes (or fasting glucose = 6.1 mmol/L), cancer, kidney, liver or bowel disease.

• Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption.

• Current smokers; history of substance abuse or alcoholism (previous weekly alcohol intake >60 units/week); current self-reported weekly alcohol intake exceeding 28 units

• Recent use of hypolipidaemic, antihypertensive, antiplatelet or antithrombotic mediations

• Platelet count above or below the normal range or any history indicative of a congenital or acquired platelet or haemostatic defect.

• Allergy or intolerance to any component of study capsules

• Unwilling to restrict consumption of any source of fish oil for the length of the study

• Subjects reporting consumption of >1 portion oily fish per week

• Weight change of >3 kg in preceding 2 months; BMI <18 and >32 kg/m2

• Blood pressure>160/90 mmHg

• Fasting blood cholesterol > 6.5 mmol/L; fasting triacylglycerol concentrations > 2.0 mmol/L

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• EPA-rich triacylglycerol oil

• Placebo - olive oil (BP specification)

• DHA-rich triacylglycerol oil

Locations

Country	Name	City	State
United Kingdom	Diabetes & Nutritional Sciences Division, King's College London	London

Sponsors (1)

Lead Sponsor	Collaborator
King's College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Platelet Monocyte Aggregates (PMA)	The endothelium plays a vital role in the regulation of blood flow, thrombosis and inflammation. Endothelium-derived anti-adhesive and anti-aggregant substances, including prostacyclin and nitric oxide, are known to inhibit platelet activation. Endothelial dysfunction or vessel wall injury lead to the activation of platelets, of which platelet-monocyte-aggregates (PMA) are a sensitive marker, and were shown to inversely correlate with markers of EF in patients with stable CHD. The measurement of PMA by flow cytometry is a method which reduces ex vivo platelet activation to its minimum and is believed to represent platelet activation in vivo.	6 weeks
Primary	Endothelial Progenitor Cell (EPC) counts	EPCs are a subgroup of circulating progenitor cells that are recruited from the bone marrow to repair the injured vasculature. They have been associated with a reduced CVD risk and may serve as markers of endothelial function because they represent a greater capacity for the endothelium to repair itself. Two populations of EPCs were measured by flow cytometry, described as 'early EPC' (KDR+/CD34+/CD133+) and 'late EPCs' (KDR+/CD34+/CD31+).	6 weeks
Secondary	Capillary density	Capillary rarefaction has been associated to CVD risk factors such as hypertension, smoking and obesity. The cutaneous circulation has emerged as an accessible and representative vascular bed to look at microvascular dysfunction. Capillary density was measured by a Capiscope (kk technologies)	6 weeks
Secondary	Arterial stiffness	Pulse wave analysis (PWA) was used to measure indices of arterial stiffness, including peripheral and central augmentation index, as well as central systolic and diastolic blood pressure. Digital volume pulse (DVP) was used to measure reflection and stiffness indices.	6 weeks
Secondary	Blood Pressure (BP) and Heart Rate (HR)	Resting HR and BP were measured in the seated and supine position after 15 minute rest, on the days of both baseline and endpoint visits. In addition, ambulatory BP and HR (24h, daytime, nighttime) was measured 2-3 days prior to each visit.	6 weeks
Secondary	Plasma isoprostane concentrations	8-iso-prostaglandin-F2a (8-IsoP-F2a), a prostaglandin F2-like compound biosynthesized nonenzymatically by a free-radical oxygenation of arachidonic acid, was measured in plasma in order to assess oxidative stress.	6 weeks
Secondary	Plasma Nitrate and Nitrites (NOx) concentrations	Plasma NOx was measured as a circulating marker of endothelial function.	6 weeks
Secondary	Serum total cholesterol concentration		6 weeks
Secondary	Serum Triacylglycerol concentrations		6 weeks
Secondary	Serum high density lipoprotein concentration		6 weeks
Secondary	Serum low density lipoprotein concentration		6 weeks
Secondary	Serum non esterified fatty acids (NEFA) concentration		6 weeks
Secondary	Serum Apolipoprotein B concentration		6 weeks
Secondary	Plasma glucose concentration		6 weeks
Secondary	Plasma insulin concentration		6 weeks
Secondary	Serum adiponectin concentration		6 weeks
Secondary	Serum resistin concentration		6 weeks
Secondary	Erythrocyte phospholipid fatty acid profiles	The EPA and DHA content of erythrocyte lipids were used as a marker of compliance.	6 weeks
Secondary	Fatty acid profile of plasma non esterified fatty acid fraction		6 weeks

External Links

•   Link